Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration

Author： Maisano Roberto   Spadaro Pietro   Toscano Giuseppe   Caristi Nicola   Pergolizzi Stefano   Salimbeni Vincenzino  

Publisher： Springer Publishing Company

ISSN： 0941-4355

Source： Supportive Care in Cancer, Vol.9, Iss.1, 2001-01, pp. : 61-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis

By Garcia-del-Muro X.   Vadell C.   Perez Manga G.   Bover I.   Rifa J.   Beltran M.   Barros M.a.M.   Germa J.R.   Fabregat X.   Moreno V.   Salvador A.   Viladiu P.  

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 193-195

Elsevier

Access to resources Recommend Favorite

Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis

By Tsukada H.   Hirose T.   Yokoyama A.   Kurita Y.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2398-2404

Elsevier

Access to resources Recommend Favorite

Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy in Patients with Acute Emesis: A Pilot Study with ACTH-Depot Plus Tropisetron

By Santini D.   Vincenzi B.   Fossati C.   D'Angelillo R.M.   Patti G.   Bianco V.   Avvisati G.   Tonini G.  

Medical Oncology, Vol. 18, Iss. 2, 2001-03 ,pp. : 131-135

Humana Press, Inc

Access to resources Recommend Favorite

Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis

By Villalon Antonio  

Supportive Care in Cancer, Vol. 12, Iss. 1, 2004-01 ,pp. : 58-63

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

By Cocquyt V.   Van Belle S.   Reinhardt R.R.   Decramer M.L.A.   O'Brien M.   Schellens J.H.M.   Borms M.   Verbeke L.   Van Aelst F.   De Smet M.   Carides A.D.   Eldridge K.   Gertz B.J.  

European Journal of Cancer, Vol. 37, Iss. 7, 2001-05 ,pp. : 835-842

Elsevier

Access to resources Recommend Favorite